Drug intelligence / Profile preview

PC-61

Development stage
Preclinical
Lead developer
BioLegend
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intraperitoneal, Intravenous
01

Overview

PC-61 is a rat monoclonal antibody (IgG1 isotype) that specifically targets the alpha chain of the interleukin-2 receptor (IL-2Rα), also known as CD25. In murine models, PC-61 is widely utilized as a research tool to deplete CD4+CD25+Foxp3+ regulatory T cells (Tregs), thereby alleviating immune suppression. This depletion is often used to study the role of Tregs in transplant rejection, autoimmune diseases, and tumor immunity. While the original clone is a rat IgG1, engineered versions with optimized Fc domains (e.g., mouse IgG2a) have been developed to enhance intratumoral Treg depletion via antibody-dependent cellular cytotoxicity (ADCC). The antibody works by blocking the binding of IL-2 to its high-affinity receptor and by inducing the clearance of CD25-high cells through effector-mediated mechanisms.

Other names
anti-CD25 antibodyanti-CD-25 antibodyanti-CD 25 antibodyanti-IL-2Rα antibodyrat anti-mouse CD25 antibodyαCD25-m2a
02

Targets

IL-2RA (Interleukin-2 receptor subunit alpha (mouse))

Beyond the preview

Go deeper on PC-61.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PC-61.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call